Non-pharmacological therapeutic strategy options for patients with dementia based on cognitive function--A Bayesian network meta-analysis of randomized controlled trials.

Non-pharmacological therapeutic strategy options for patients with dementia based on cognitive function--A Bayesian network meta-analysis of randomized controlled trials. Ageing Res Rev. 2019 Oct 31;:100965 Authors: Liang JH, Lin L, Wang YQ, Jia RX, Qu XY, Li J, Li JY, Qian S, Qian YX, Wang S, Gao Z, Cheng XX, Xu Y Abstract Dementia represents one of the most common neurodegenerative disorders in older adults. However, it is still unclear whether non-pharmacological therapies (NPTs) are effective or not and which treatment should be preferred. We applied a series of search strategies to identify eligible randomized controlled trials on 1st October, 2018, investigating the effects of NPTs of dementia in the older persons. Pairwise and network meta-analyses were sequentially performed. A total of 31 trials were included, which enrolled 1895 participants and 7 NPTs. Compared with control group, all the NPTs included were statistically beneficial to cognitive function, and our study indicated Comprehensive Therapy(CT) [the surface under the cumulative ranking curve(SUCRA=92.42%)] might be the best choice for dementia patients. Our study suggests CT might be the optimal NPT for improving the cognitive function of dementia patients. However, the above conclusions need to be further analyzed. PMID: 31678652 [PubMed - as supplied by publisher]
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Tags: Ageing Res Rev Source Type: research

Related Links:

Conditions:   Dementia;   Sleep Disorder;   Mild Cognitive Impairment;   Phototherapy Interventions:   Device: Green LED light;   Device: Red LED light (placebo) Sponsor:   Kaohsiung Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Agitation in Patients With Dementia of the Alzheimer's Type Interventions:   Drug: AVP-786;   Drug: Placebo Sponsor:   Avanir Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Frontotemporal Dementia Intervention:   Biological: PR006 Sponsor:   Prevail Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The antidepressant bupropion was no better than placebo in reducing apathy in nondepressed patients with Alzheimer-type dementia in a randomized controlled trial.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Psychiatry News Source Type: news
Safeguarding adults with dementia is an important part of everyday work for providers of adult social care. This quick guide aims to support care providers and staff to safeguard people with dementia during the crisis. There are increased concerns that, during the COVID-19 crisis, people may be more vulnerable to abuse or neglect.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
The intent of this trans-NIH initiative would be to invite research to determine the role and impact of digital health interventions (e.g., mobile health (mHealth), telemedicine and telehealth, health information technology, wearable devices) to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and other vulnerable populations (e.g., essential medical personnel, emergency responders, and frontline workers in essential businesses or services; people who are residents of chronic care facilities, co...
Source: National Institute of Mental Health - Category: Psychiatry Authors: Source Type: news
DiscussionIf PROMs are helpful in improving patient outcomes for depression even to a small extent, then they are likely to be good value for money, given their low cost. The benefits could be considerable, given that depression is common, disabling, and costly.Trial registrationISRCTN no: 17299295. Registered 1st October 2018.
Source: Trials - Category: Research Source Type: clinical trials
ConclusionCollectively these findings highlight the utility of targeted MS approaches to quantify biomarkers associated with AD that could be used for monitoring disease progression, stratifying patients for clinical trials and measuring therapeutic response.
Source: Clinical Proteomics - Category: Biochemistry Source Type: research
Conclusions: These results suggest that attention to specific depressive symptom profile can improve diagnostic sensitivity and can be used to provide more individualized patient care.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
DEMENTIA is an umbrella term for a number of conditions characterised by a decline in cognitive abilities. Speech problems are one of the first casualties - here are eight warning signs to watch out for.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
More News: Brain | Dementia | Genetics | Neurology | Neuroscience | Science | Statistics | Study